CD79A and myeloid sarcoma: Rodrigo et al. included 72 MS cases and 123 healthy controls and found the antibodies (IgA-anti-transglutaminase-2) in 10% of MS cases and 2.4% (p < 0.05) (OR = 5.3) while HLA-DQ2 markers did not significantly differ between patients and healthy subjects [31].